Intravenous L-arginine reduces VE/VCO2 slope acutely in patients with severe chronic heart failure.
Banning
A P
AP
Department of Cardiology, University Hospital of Wales, Heath Park, Cardiff, UK.
Prendergast
B
B
D001120:Arginine / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D001944:Breath Tests; D002245:Carbon Dioxide / Q000032:analysis*; D002908:Chronic Disease; D018592:Cross-Over Studies; D005080:Exercise Test; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage; D011379:Prognosis; D011659:Pulmonary Gas Exchange / Q000187:drug effects*; D012720:Severity of Illness Index; D016037:Single-Blind Method; D014665:Vasodilator Agents / Q000008:administration & dosage
D014665:Vasodilator Agents; D002245:Carbon Dioxide; D001120:Arginine; D009543:Nifedipine